All Updates

All Updates

icon
Filter
Funding
Avicenna Biosciences raises USD 6 million in debt financing to accelerate drug development
AI Drug Discovery
Feb 25, 2024
This week:
Partnerships
Apple discloses use of AWS GenAI chips at re:Invent 2024 conference
Generative AI Infrastructure
Today
Product updates
AWS launches Automated Reasoning checks to combat AI hallucinations
Generative AI Infrastructure
Today
Product updates
Roonyx releases enhanced BNPL platform to facilitate secure transactions
Buy Now, Pay Later
Yesterday
Product updates
AWS announces next generation of SageMaker platform at re:Invent 2024
Generative AI Infrastructure
Yesterday
Product updates
Equal1 launches quantum controller chip for cryogenic computing
Quantum Computing
Yesterday
Partnerships
Exotec partners with BlueStar to deploy Skypod warehouse automation system
Logistics Tech
Yesterday
Partnerships
Amaero enters long-term supply agreement with Perryman
Additive Manufacturing
Yesterday
Product updates
Raise3D launches six new resins for DF2 DLP solution
Additive Manufacturing
Yesterday
M&A
Anzu Partners acquires voxeljet for EUR 20 million
Additive Manufacturing
Yesterday
Funding
Soda Health raises USD 50 million in oversubscribed Series B funding to scale operations
Health Benefits Platforms
Yesterday
AI Drug Discovery

AI Drug Discovery

Feb 25, 2024

Avicenna Biosciences raises USD 6 million in debt financing to accelerate drug development

Funding

  • Durham-based AI drug developer Avicenna Biosciences has secured USD 6 million in debt financing according to a Securities and Exchange Commission (SEC) filing.

  • The funds will fuel the company’s ongoing drug discovery and development process to treat neurodegenerative diseases.

  • Founded in 2020, Avicenna Biosciences leverages machine learning-enhanced medicinal chemistry for drug development. This approach is designed to streamline the lead-to-candidate optimization process for small-molecule drug development. Currently, the company is focused on developing a treatment for Amyotrophic Lateral Sclerosis, a progressive neurodegenerative disease.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.